Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:Joyce AllaireLifeSci Advisors212-915-2569jallaire@lifesciadvisors.com
Media Contact:Debra CharlesworthVera Therapeutics415-854-8051corporatecommunications@veratx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Ispire Malaysia Reaffirms Full Regulatory Compliance and Export-Only Manufacturing Operations
LOS ANGELES, June 9, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that its Malaysian subsidiary, Ispire Malaysia Sdn Bhd ("Ispire Malaysia"), reaffirmed its strict compliance with all applicable Malaysian laws and regulations. This clarification follows recent media reports and public interest concerning the Company's manufacturing activities in Malaysia. Ispire Malaysia confirms that all manufacturing activities at its facility in Johor are exclusively for export purposes and do not involve the production or distribution of any nicotine- or cannabis-containing liquids or gels within Malaysia and for export. "Ispire Malaysia operates under stringent procedures to ensure all manufacturing is 100% export-oriented," said Michael Wang, Co-CEO of Ispire Technology Inc. "We believe our operations fully comply with Malaysian law, and we are committed to transparency and regulatory cooperation at both federal and state levels." Key Clarifications: No Local Distribution: All products manufactured in Malaysia are not sold, distributed, or marketed in the Malaysian market. No Nicotine or Cannabis Content: The facility produces semi-finished vaporizer hardware only, with no liquids or gels involved at any point in production. No Medical Devices Manufactured: While the facility is capable of producing certified components, no medical devices are currently manufactured. Any future activity in this sector would follow a comprehensive regulatory review. Advanced Safety Features: Ispire products will integrate blockchain-based age-gating and geo-fencing technology, ensuring use is restricted to adults and compliant areas. The company's patented technology has been submitted for review by the U.S. Food and Drug Administration. The Company also noted that recent commentary referencing cannabis-related products was based on marketing materials related to Ispire's U.S. operations, which operate in jurisdictions where such products are legal. These materials do not reflect the nature of the Company's business conducted in Malaysia. With an investment target exceeding USD 50 million, Ispire Malaysia has positioned itself as a premier manufacturing hub in Southeast Asia, supporting job creation and technological innovation aligned with Malaysia's industrial development goals. "We remain committed to upholding the highest standards of compliance, safety, and corporate responsibility," said Wang. For further information, please visit About Ispire Technology is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit or follow Ispire on Instagram, LinkedIn, Twitter and YouTube. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company meeting its investment target in Malaysia as currently planned, to a lesser degree, or at all; the Company's continued compliance with applicable laws and regulations in the jurisdictions in which it operates; the approval or rejection of any PMTA submitted by the Company; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals regarding age-gating technology, or otherwise, as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's business strategies; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC, including the Ispire's Quarterly Report on Form 10-Q for the period ended March 31, 2025. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect. IR Contacts:For more information, kindly contact:Investor RelationsSherry Zheng718.213.7386ir@ Strategic CommunicationsPhil Carlson212.896.1233ispire@ Contact:Ellen Mellody570.209.2947ispire@ View original content: SOURCE Ispire Technology Inc.
Business Wire
36 minutes ago
- Business Wire
Securities Fraud Investigation Into Lineage, Inc. (LINE) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lineage, Inc. ('Lineage' or the 'Company') (NASDAQ: LINE) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON LINEAGE, INC. (LINE), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On April 30, 2025, Lineage reported first quarter 2025 financial results, including that '[t]otal revenue decreased (2.7)%' to $1.29 billion for the quarter. The Company stated it 'experienced more normal seasonal trends in the first quarter after multiple years of elevated inventory levels.' On this news, Lineage's stock price fell $8.26, or 14.62%, to close at $48.23 per share on April 30, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Lineage should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
an hour ago
- Yahoo
Cibus, Inc. Announces Closing of $27.5 Million Public Offering
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the 'Company' or 'Cibus'), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the closing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' board of directors (5,714,286 shares). All of the shares of Class A Common Stock in the offering were sold by Cibus. The gross proceeds of the offering were $27.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund further development of the Company's weed management productivity traits in Rice and for working capital and general corporate purposes, as it pursues longer-term financing. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-273062), including base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC'), and declared effective on October 27, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering were filed with the SEC and are available on the SEC's website located at Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Cibus Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus' long-term focus is productivity traits for major, large-acreage row crops. Cibus is not a seed company. It is a technology company that uses proprietary high-throughput gene editing technology to develop crop traits at a fraction of the time and cost of conventional breeding and to license them to seed companies in exchange for royalties on seed sales. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as 'anticipates,' 'believes,' 'continue,' 'estimates,' 'expects,' 'intends,' 'may,' 'might,' 'plans,' 'predicts,' 'projects,' 'should,' 'targets,' 'will,' or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected use of the proceeds from the offering. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus' management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law. CIBUS CONTACTS: INVESTOR RELATIONSKaren Troeberktroeber@ Jeff Sonnek – MEDIA RELATIONSColin Sanfordcolin@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
